FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine and concerns an "antibody-drug" conjugate for treating cancer of the following formula (I): 
or its pharmaceutically acceptable salt. Where Ab is a target antibody or anti-antigen antibody, or a target-binding fragment thereof or an antigen-binding fragment thereof; L is a linker of formula (III):
;
D represents a drug group. Group of inventions also relates to a composition for treating cancer comprising at least one said "antibody-drug" conjugate; method of treating target- or antigen-expressing cancer in a subject, comprising administering an effective amount of at least one said "antibody-drug" conjugate.
EFFECT: group of inventions provides improved biological activity of the drug.
26 cl, 27 ex, 30 dwg, 15 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| CONJUGATE OF ANTI-IGF-1R ANTIBODY WITH DRUG AND USE THEREOF FOR TREATING CANCER | 2015 |
|
RU2692563C2 |
| COMPOSITION FOR TREATING IGF-1R EXPRESSING CANCER | 2016 |
|
RU2728568C2 |
| SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES | 2019 |
|
RU2815199C2 |
| NEW CONJUGATES BINDING COMPOUND - ACTIVE COMPOUND (ADC) AND USE THEREOF | 2012 |
|
RU2610336C2 |
| STABILITY-MODULATING LINKERS FOR USE WITH ANTIBODY DRUG CONJUGATES | 2015 |
|
RU2680238C2 |
| CYTOTOXIC PEPTIDES AND ANTIBODY-DRUG CONJUGATES THEREOF | 2012 |
|
RU2586885C2 |
| DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | 2014 |
|
RU2662951C2 |
| ANTIBODY-DRUG CONJUGATES (ADC) WHICH BIND TO FLT3 PROTEINS | 2016 |
|
RU2739617C2 |
| PYRROLOBENZODIAZEPINE CONJUGATES | 2017 |
|
RU2744200C2 |
| LOW-MOLECULAR CONJUGATES FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | 2011 |
|
RU2629957C2 |
